Solomon Langermann
Director Técnico/Científico/I+D en NEXTCURE, INC. .
Fortuna: 48 171 $ al 30/04/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Michael Richman | M | 63 |
Amplimmune, Inc.
 Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | 17 años |
| David Kabakoff | M | 76 |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | 9 años |
| Joshua Weiyuan Wang | M | - |
Verimmune, Inc.
 Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Chau Khuong | M | 48 | 9 años | |
| Elaine Jones | M | 69 | 9 años | |
| John Troyer | M | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Stephen Webster | M | 63 | 5 años | |
| Anne Borgman | M | 56 | 3 años | |
| Ellen Feigal | M | 69 | 3 años | |
| John Houston | M | 64 | 4 años | |
| Timothy Mayer | M | 59 | 8 años | |
| Cynthia Poa | F | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Kevin Koh | M | - |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Sourav Kundu | M | 64 | 3 años | |
| Roger Pomerantz | M | 67 |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Han Myint | M | 71 | 3 años | |
| Sebastien Maloveste | M | - | - | |
| Eric Richman | M | 63 |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Verimmune, Inc. is a company based in Washington that is dedicated to developing a first-in-class cancer immunotherapy called anti-tumor immune redirection (AIR). Verimmune's proprietary virus-inspired particle (VIP) technology platform redirects pre-existing pathogenic or childhood vaccine immune memory toward tumors. The American company's lead immuno-oncology product candidate, Veri-101, harnesses the cellular immune memory responses from prior cytomegalovirus (CMV) infection to fight cancer. This mechanism of action has the potential to redefine the treatment paradigm for patients with untreatable cancers or resistance to existing therapies. The company was founded in 1995 by John Troyer and Joshua Weiyuan Wang, with Joshua Weiyuan Wang serving as the CEO since then. | - |
| Steven Cobourn | M | 61 | 6 años | |
| Kevin Shaw | M | 50 | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Jeff Jones | M | 52 |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 10 años |
| Drew Pardoll | M | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Derace L. Schaffer | M | 76 |
PharmAthene, Inc. /Old/
 PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 2 años |
| Stella Xu | M | 53 | 3 años | |
| Judith Li | F | 40 | 5 años | |
| Garry Nicholson | M | 69 | 3 años | |
| Linda N. Liu | M | 57 |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | 15 años |
| James B. Bingham | M | 57 |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | 14 años |
| Charles G. Drake | M | 83 |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Elizabeth Jaffee | M | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Lie Ping Chen | M | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Jonathan D. Powell | M | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Briggs Morrison | M | 65 | 2 años | |
| John Mekalanos | M | - |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | - |
| Elizabeth Czerepak | F | 58 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 4 años |
| Andrea Cox | M | - |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | - |
| Timothy Shannon | M | 65 | 5 años | |
| Joel W. McCleary | M | 75 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 6 años |
| Michael Yi | M | - | - | |
| Valerie D. Riddle | M | 63 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 4 años |
| James Cavanaugh | M | 87 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | - |
| Ronald W. Kaiser | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 años |
| Ansbert Gadicke | M | 66 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 3 años |
| David P. Wright | M | 75 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 4 años |
| Matthew Kinley | M | 56 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | - |
| Mack Gill | M | 72 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 3 años |
| Wayne A. Schellhammer | M | 70 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 años |
| Edward B. Berger | M | 95 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 2 años |
| Christopher C. Camut | M | 61 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | - |
| Richard Schoenfeld | M | - |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 2 años |
| Wayne Morges | M | 76 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 2 años |
| Francesca M. Cook | F | 58 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 4 años |
| Marc A. Cohen | M | 61 |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | 1 años |
| Steven St. Peter | M | 57 |
PharmAthene, Inc. /Old/
PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD. | 3 años |
| Kevin N. Heller | M | 53 | 2 años |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 55 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Solomon Langermann
- Red Personal
